Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyDNA repair targeted therapy: The past or future of cancer treatment?Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesPersonalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.ATR/CHK1 inhibitors and cancer therapy.Docking-based 3D-QSAR study of pyridyl aminothiazole derivatives as checkpoint kinase 1 inhibitors.
P2860
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Discovery of 3-alkoxyamino-5-( ...... bioavailable CHK1 inhibitors.
@en
type
label
Discovery of 3-alkoxyamino-5-( ...... bioavailable CHK1 inhibitors.
@en
prefLabel
Discovery of 3-alkoxyamino-5-( ...... bioavailable CHK1 inhibitors.
@en
P2093
P2860
P356
P1476
Discovery of 3-alkoxyamino-5-( ...... y bioavailable CHK1 inhibitors
@en
P2093
Alexis K de Haven Brandon
Angela Hayes
G Wynne Aherne
Ian Collins
John C Reader
Kathy J Boxall
Melanie R Valenti
Michael I Walton
Michael Lainchbury
P2860
P304
10229-10240
P356
10.1021/JM3012933
P407
P50
P577
2012-10-19T00:00:00Z